Company / Cash & Equivalents
Century Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$61.9M
FY2025
5-year range
$47.3M / $84.3M
FY2022-FY2025
Trend
+5.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $47M to $62M over the past 2 years.
Based on SEC 10-K filings.
$62M in FY2025 with a 3-year CAGR of -9.8%.
Improved from $47M to $62M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -9.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -9.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 5.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $61.9M | +5.8% |
| FY2024 | $58.4M | +23.5% |
| FY2023 | $47.3M | -43.8% |
| FY2022 | $84.3M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026